The size of the Bladder Cancer Therapeutics market in the Asia Pacific is expected to reach USD 62.38 million by 2025 from USD 47.32 million in 2020 growing at a CAGR of 5.68% from 2020 to 2025
Bladder cancer is aroused due to malignancy of urinary bladder lining with epithelial cells. The bladder is an organ present at the lower part of the abdomen and stores urine. Over developing of these epithelial cells results in blabber cancer and it can be of many types such as transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. At the present number of therapies have been evolved for the management of bladder cancers include chemotherapies, immunotherapies, surgeries, radiation therapies, and other therapies.
Rising healthcare expenditure, increasing the cancer patient population, the growing involvement of universities & research institutes, and the rising focus of foreign pharmaceutical companies on the Asian market are driving the growth of the bladder cancer therapeutics market in Asia-Pacific. However, unawareness among bladder cancer patients about advanced cancer therapies and the presence of more generic bladder cancer therapeutics are constraining the growth of the bladder cancer therapeutics market in Asia-Pacific.
This research report on the APAC Bladder Cancer Therapeutics Market has been segmented and sub-segmented into the following categories
By Type:
By Treatment:
By Country:
Companies dominating the APAC Bladder Cancer Therapeutics Market profiled in this report are Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Celgene Corporation (U.S.).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Non Muscle Invasive/Superficial Bladder Cancer
5.1.3 Invasive Bladder Cancer
5.1.4 Squamous Cell Bladder Cancer
5.1.5 Adenocarcinoma of the Bladder
5.1.6 Rare Bladder Cancers
5.2 By Treatment
5.2.1 Surgery
5.2.1.1 Transurethral Bladder Tumor Resection (TURBT)
5.2.1.2 Cystectomy
5.2.1.3 Urinary Diversion
5.2.2 Chemotherapy
5.2.3 Immunotherapy
5.2.4 Radiation Therapy
5.2.5 Intravesical Therapy
6. Geographical Analysis
6.1 Asia-Pacific
6.1.1 Introduction
6.1.2 China
6.1.3 India
6.1.4 Japan
6.1.5 South Korea
6.1.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Sanofi S.A. (France)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 GlaxoSmithKline plc (U.K.)
9.5 Eli Lilly and Company (U.S.)
9.6 AstraZeneca plc (U.K.)
9.7 Bristol-Myers Squibb (U.S.)
9.9 F. Hoffmann-La Roche Ltd. (Switzerland)
9.10 Celgene Corporation (U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
